Sino Biopharmaceutical Ltd - Company Profile
Powered by 
All the sales intelligence you need on Sino Biopharmaceutical Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Sino Biopharmaceutical Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Sino Biopharmaceutical Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Sino Biopharmaceutical Ltd (Sino Biopharma), a subsidiary of Charoen Pokphand Group Co Ltd, is a research-oriented pharmaceutical company that develops, manufactures, and markets medicines, biopharmaceuticals, and Chinese medicines. It offers medicines for the treatment of hepatitis, cardio-cerebral diseases, cancer, orthopedic conditions, infectious diseases, and respiratory and digestive diseases, among others. The company offers products in various dosage forms including large-volume injections, PVC-free soft bags for intravenous injections, small-volume injections, powdered medicines, granulated medicines, capsules and tablets. It works in partnership with several domestic and foreign pharmaceutical companies to advance the development of its products. Sino Biopharma is headquartered in Wanchai, Hong Kong.
Headquarters
Hong Kong
Address
Unit 09, 41f, Office Tower, Convention Plaza, No. 1 Harbour Road, Wanchai, Hong Kong City
Website
www.sinobiopharm.com
Telephone
852 28029886
No of Employees
24,379
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
1177 (HKG)
Revenue (2024)
$4.4B
10.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-33%
(2024 vs 2023)
Market Cap*
$10.5B
Net Profit Margin (2024)
XYZ
-39.3%
(2024 vs 2023)
* As of and is in US$
Sino Biopharmaceutical Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Hepatitis Medicines: | Jiuli |
| Diammonium Glycyrrhizinate Enteric-coated Capsules | Tianjie |
| Entecavir Dispersible Tablets | Aisuping |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In May, the company received acceptance from China’s National Medical Products Administration for M701 CD3/EpCAM Bispecific Antibody for the treatment of malignant ascites caused by advanced epithelial malignancies. |
| 2026 | Corporate Changes/Expansions | In March, the company announced a stock short name for trading in the shares of the Company on The Stock Exchange of Hong Kong Limited changed from SINO BIOPHARM to SBP GROUP. |
| 2026 | Contracts/Agreements | In March, CTTQ Pharma entered into a licensing agreement with Sanofi for Rovadicitinib, a first-in-class oral small-molecule JAK/ROCK inhibitor. |
Competitor Comparison
| Key Parameters | Sino Biopharmaceutical Ltd | China Resources Pharmaceutical Group Ltd | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Jiangsu Hengrui Pharmaceuticals Co Ltd | The United Laboratories International Holdings Ltd |
|---|---|---|---|---|---|
| Headquarters | Hong Kong | Hong Kong | China | China | Hong Kong |
| City | Hong Kong City | Hong Kong City | Shanghai | Lianyungang | Hong Kong City |
| State/Province | - | - | Shanghai | Jiangsu | - |
| No. of Employees | 24,379 | 85,600 | 40,603 | 20,602 | 17,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Tse, Eric S Y | Chief Executive Officer; Director | Executive Board | 2022 | 29 |
| Theresa Tse | Chairwoman | Executive Board | 2015 | 32 |
| Sean Chen | Chief Strategy Officer | Senior Management | - | 46 |
| Kang Xiaoyan | Chief Medical Officer | Senior Management | 2026 | - |
| Tse Ping | Senior Vice Chairman | Executive Board | 2020 | 73 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer